×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
XFOR – x4 pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
XFOR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/19
09:14 am
xfor
Biopharma Leaders of Color (BLOC) Announces Board of Directors and Establishes Executive Council to Expand and Enhance Offerings [Yahoo! Finance]
Low
Report
Biopharma Leaders of Color (BLOC) Announces Board of Directors and Establishes Executive Council to Expand and Enhance Offerings [Yahoo! Finance]
11/14
01:34 pm
xfor
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its price target lowered by analysts at HC Wainwright from $5.00 to $1.50. They now have a "buy" rating on the stock.
High
Report
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its price target lowered by analysts at HC Wainwright from $5.00 to $1.50. They now have a "buy" rating on the stock.
11/14
08:15 am
xfor
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its price target lowered by analysts at Stifel Nicolaus from $5.00 to $4.00. They now have a "buy" rating on the stock.
High
Report
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its price target lowered by analysts at Stifel Nicolaus from $5.00 to $4.00. They now have a "buy" rating on the stock.
11/14
08:12 am
xfor
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference [Yahoo! Finance]
High
Report
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference [Yahoo! Finance]
11/14
08:00 am
xfor
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
High
Report
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
11/14
02:21 am
xfor
X4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ... [Yahoo! Finance]
High
Report
X4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ... [Yahoo! Finance]
11/13
06:16 am
xfor
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/13
06:07 am
xfor
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
High
Report
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2024
06:07 am
xfor
x4 pharmaceuticals, inc.
MISS
Report
-57.8%
x4 pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
04:32 pm
xfor
Form 4 X4 Pharmaceuticals, Inc For: Nov 15 Filed by: Ragan Paula
Medium
Report
Form 4 X4 Pharmaceuticals, Inc For: Nov 15 Filed by: Ragan Paula
11/15
04:12 pm
xfor
Form 144 X4 Pharmaceuticals, Inc Filed by: Ragan Paula
Medium
Report
Form 144 X4 Pharmaceuticals, Inc Filed by: Ragan Paula
11/13
09:03 am
xfor
Form 10-Q X4 Pharmaceuticals, Inc For: Sep 30
High
Report
Form 10-Q X4 Pharmaceuticals, Inc For: Sep 30
11/13
08:12 am
xfor
Form 8-K X4 Pharmaceuticals, Inc For: Nov 13
High
Report
Form 8-K X4 Pharmaceuticals, Inc For: Nov 13
11/13
06:13 am
xfor
Form 8-K X4 Pharmaceuticals, Inc For: Nov 13
High
Report
Form 8-K X4 Pharmaceuticals, Inc For: Nov 13
11/12
06:00 pm
xfor
Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: VANGUARD GROUP INC
High
Report
Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: VANGUARD GROUP INC
11/8
02:18 pm
xfor
Form SC 13G X4 Pharmaceuticals, Inc Filed by: BlackRock, Inc.
Medium
Report
Form SC 13G X4 Pharmaceuticals, Inc Filed by: BlackRock, Inc.
11/4
02:16 pm
xfor
Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: VANGUARD GROUP INC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating.
33.7%
2/8 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock. 13.1%
2/14 Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: Cormorant Asset Management, LP 10.5%
4/1 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 8.4%
7/30 X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM Syndrome 8.2%
6/7 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 7.5%
4/9 X4 Pharmaceuticals to Present and Participate in the Virtual 19th Annual Needham Healthcare Conference 7.3%
12/23 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $20.00 price target on the stock. 5.8%
11/10 X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.7%
2/28 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 5.3%
2/8 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock. 13.1%
2/14 Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: Cormorant Asset Management, LP 10.5%
4/1 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 8.4%
7/30 X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM Syndrome 8.2%
6/7 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 7.5%
4/9 X4 Pharmaceuticals to Present and Participate in the Virtual 19th Annual Needham Healthcare Conference 7.3%
12/23 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $20.00 price target on the stock. 5.8%
11/10 X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.7%
2/28 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 5.3%
TOP News Decliners
3/20
Form 8-K X4 Pharmaceuticals, Inc For: Mar 18
-29.5%
4/1 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -18.3%
3/17 Form 8-K X4 Pharmaceuticals, Inc For: Mar 13 -17.5%
11/26 X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants -16.8%
3/26 X4 Pharmaceuticals Inc (NASDAQ: XFOR) had its price target lowered by analysts at Citigroup Inc from $16.00 to $15.00. They now have a "buy" rating on the stock. -15.8%
9/20 Form 8-K X4 Pharmaceuticals, Inc For: Sep 18 -12.4%
3/13 Form S-8 X4 Pharmaceuticals, Inc -12.1%
5/17 Form 8-K/A X4 Pharmaceuticals, Inc For: Mar 29 -9.0%
9/14 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.5%
5/15 X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia -7.4%
4/1 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -18.3%
3/17 Form 8-K X4 Pharmaceuticals, Inc For: Mar 13 -17.5%
11/26 X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants -16.8%
3/26 X4 Pharmaceuticals Inc (NASDAQ: XFOR) had its price target lowered by analysts at Citigroup Inc from $16.00 to $15.00. They now have a "buy" rating on the stock. -15.8%
9/20 Form 8-K X4 Pharmaceuticals, Inc For: Sep 18 -12.4%
3/13 Form S-8 X4 Pharmaceuticals, Inc -12.1%
5/17 Form 8-K/A X4 Pharmaceuticals, Inc For: Mar 29 -9.0%
9/14 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.5%
5/15 X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia -7.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: